CUE BIOPHARMA INC (CUE) Stock News
NASDAQ:CUE - Nasdaq - US22978P1066 - Common Stock - Currency: USD
CUE Latest News, Press Relases and Analysis
What's going on in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC12-month landmark survival of 88% and mOS of 32 months BOSTON, July 01, 2025 (GLOBE NEWSWIRE)...
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified...
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of -21.43% and 78.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: FENC
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in...
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of 0% and 7.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MXCT
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline
Opus Genetics, Inc. (IRD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: IRD
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know
Cue Biopharma (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: HRMY
Jim Cramer on Micron (MU): “No Catalyst, But You’re Buying Near the Low End”
We recently published a list of Jim Cramer Recently Discussed These 9 Stocks. In this article, we are going to take a look at where Micron Technology, Inc. (NASDAQ:MU) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money, discussed the current economic outlook on Monday as he outlined […]
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Announces Proposed Public Offering
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma to Host Business Update Call and Webcast
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.The agreement...
What's Going On With Cue Biopharma Shares Tuesday?
Cue reported 2024 fiscal-year earnings on Monday after the market closed.
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of 18.75% and 5.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Mentions: NRIX
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class...
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Cue Biopharma Announces Strategic Organizational Transition
Cue Biopharma Announces Strategic Organizational Transition
Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri,...
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
Objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months in first line (1L) HPV+...